Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
出版年份 2022 全文链接
标题
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-02-04
DOI
10.1016/s1470-2045(21)00758-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
- (2019) Francesco Perrone et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
- (2018) Sabino De Placido et al. LANCET ONCOLOGY
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
- (2017) Ian Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
- (2016) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
- (2016) Meritxell Bellet et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- (2015) LANCET
- Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
- (2015) Jürg Bernhard et al. LANCET ONCOLOGY
- Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
- (2014) M. Gnant et al. ANNALS OF ONCOLOGY
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
- (2013) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
- (2012) Hiroyuki Takei et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
- (2012) Norikazu Masuda et al. LANCET ONCOLOGY
- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care
- (2011) R Peto BRITISH JOURNAL OF CANCER
- Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
- (2011) Georg Pfeiler et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started